Spotlight on Neurology

Credits: 0.50 AANP / CME
Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 2: The Evolving Management Landscape in Alzheimer’s Disease: From Pathophysiology to Emerging Therapies
Sharon Cohen, MD, FRCPC
Global Education Group

Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 2: The Evolving Management Landscape in Alzheimer’s Disease: From Pathophysiology to Emerging Therapies

Start

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss clinically relevant aspects of AD pathophysiology, including amyloid β and tau
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Barring significant clinical efforts and medical breakthroughs that prevent or slow disease development, current estimates suggest that by 2050, AD will afflict 14 million patients in the United States.1 Clearly, the development of AD is complex, presenting a target-rich clinical environment for both diagnostic approaches and therapeutic interventions. Amyloid plaques and neurofibrillary tangles are the primary pathophysiologic characteristics of AD.2 Among other approaches, amyloid-targeted therapies have been directed toward protofibrils, monomers, oligomers, and existing plaques.3 Neurofibrillary tangles have emerged as another therapeutic target over the last several years, including agents targeting tau expression, stabilizing tau conformations, or clearing tau aggregates.4 Thus far, amyloid-targeted therapies are further advanced in clinical development, and as the potential for approval grows, clinicians must be aware of mechanism of action, clinical trial data, and patient selection. In this activity, Dr. Cohen reviews the pathophysiology of AD, individual therapeutic targets, and amyloid- and tau-directed therapies as well as other therapeutic approaches.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Jeong S. Mol Cells. 2017;40(9):613-620.
  3. Panza F, et al. Nat Rev Neurol. 2019;15(2):73-88.
  4. Graham WV, et al. Annu Rev Med. 2017;68:413-430.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss clinically relevant aspects of AD pathophysiology, including amyloid β and tau
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Barring significant clinical efforts and medical breakthroughs that prevent or slow disease development, current estimates suggest that by 2050, AD will afflict 14 million patients in the United States.1 Clearly, the development of AD is complex, presenting a target-rich clinical environment for both diagnostic approaches and therapeutic interventions. Amyloid plaques and neurofibrillary tangles are the primary pathophysiologic characteristics of AD.2 Among other approaches, amyloid-targeted therapies have been directed toward protofibrils, monomers, oligomers, and existing plaques.3 Neurofibrillary tangles have emerged as another therapeutic target over the last several years, including agents targeting tau expression, stabilizing tau conformations, or clearing tau aggregates.4 Thus far, amyloid-targeted therapies are further advanced in clinical development, and as the potential for approval grows, clinicians must be aware of mechanism of action, clinical trial data, and patient selection. In this activity, Dr. Cohen reviews the pathophysiology of AD, individual therapeutic targets, and amyloid- and tau-directed therapies as well as other therapeutic approaches.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Jeong S. Mol Cells. 2017;40(9):613-620.
  3. Panza F, et al. Nat Rev Neurol. 2019;15(2):73-88.
  4. Graham WV, et al. Annu Rev Med. 2017;68:413-430.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Neurology Presentations

0.50 AANP / CME
Global Education Group
Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 1: Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 1: Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

Start

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Assess patients with mild cognitive impairment and Alzheimer’s disease using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms.1 Mild cognitive impairment (MCI) affects a large percentage of preclinical AD patients, and studies have found that 32% to 38% of patients with MCI will develop AD within 5 years.2,3 Early diagnosis, while challenging, is critical to initiate nonpharmacologic and pharmacologic therapy targeting symptoms of MCI or AD, as well as to allow for long-term planning.4 Guidelines recommend that standardized cognitive tests be applied in addition to patient and caregiver interviews to determine risk for and symptoms of MCI or AD.5 Standard imaging, including magnetic resonance imaging (MRI) and possibly fluorodeoxyglucose (FDG)-positron emission tomography (PET), is useful to rule out causes other than AD, although it is insufficient for diagnosis on its own.6 The diagnosis of AD is rapidly evolving from one of exclusion to one of inclusion by employing established biomarkers—both in cerebrospinal fluid and amyloid or tau PET tracers—to confirm diagnosis. As research continues to evolve and diagnostic capabilities expand, clinicians must remain up to date on new guidelines, technologies, and strategies to identify appropriate patients for further testing. Dr. Cohen and Dr. Sabbagh provide expert insight into risk factors for MCI and AD, symptoms indicative of MCI or AD, neuropsychologic testing, standard imaging, and the evolving future of MCI and AD diagnosis.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Mitchell AJ, Shiri-Feshki M. Acta Psychiatr Scand. 2009;119(4):252-265.
  3. Ward A, et al. Dement Geriatr Cogn Dis Extra. 2013;3(1):320-332.
  4. Dubois B, et al. J Alzheimers Dis. 2016;49(3):617-631.
  5. Petersen RC, et al. Neurology. 2018;90(3):126-135.
  6. Femminella GD, et al. Int J Mol Sci. 2018;19(12):3702.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada


Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Assess patients with mild cognitive impairment and Alzheimer’s disease using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms.1 Mild cognitive impairment (MCI) affects a large percentage of preclinical AD patients, and studies have found that 32% to 38% of patients with MCI will develop AD within 5 years.2,3 Early diagnosis, while challenging, is critical to initiate nonpharmacologic and pharmacologic therapy targeting symptoms of MCI or AD, as well as to allow for long-term planning.4 Guidelines recommend that standardized cognitive tests be applied in addition to patient and caregiver interviews to determine risk for and symptoms of MCI or AD.5 Standard imaging, including magnetic resonance imaging (MRI) and possibly fluorodeoxyglucose (FDG)-positron emission tomography (PET), is useful to rule out causes other than AD, although it is insufficient for diagnosis on its own.6 The diagnosis of AD is rapidly evolving from one of exclusion to one of inclusion by employing established biomarkers—both in cerebrospinal fluid and amyloid or tau PET tracers—to confirm diagnosis. As research continues to evolve and diagnostic capabilities expand, clinicians must remain up to date on new guidelines, technologies, and strategies to identify appropriate patients for further testing. Dr. Cohen and Dr. Sabbagh provide expert insight into risk factors for MCI and AD, symptoms indicative of MCI or AD, neuropsychologic testing, standard imaging, and the evolving future of MCI and AD diagnosis.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Mitchell AJ, Shiri-Feshki M. Acta Psychiatr Scand. 2009;119(4):252-265.
  3. Ward A, et al. Dement Geriatr Cogn Dis Extra. 2013;3(1):320-332.
  4. Dubois B, et al. J Alzheimers Dis. 2016;49(3):617-631.
  5. Petersen RC, et al. Neurology. 2018;90(3):126-135.
  6. Femminella GD, et al. Int J Mol Sci. 2018;19(12):3702.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada


Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

0.25 AANP / CME
Global Education Group
Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 4: Addressing the Clinical Infrastructure for Alzheimer’s Disease: Potential Changes to Reduce Capacity Limitations and Facilitate Access to Care

Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 4: Addressing the Clinical Infrastructure for Alzheimer’s Disease: Potential Changes to Reduce Capacity Limitations and Facilitate Access to Care

Start

Activity Details

Free CME/AANP
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Detail clinical infrastructure changes that may be needed to address the growing population of patients with AD and new treatment options

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Though there are currently only symptomatic therapies available, amyloid- and tau-targeted therapies are on the horizon. With the approval of new therapies for AD, particularly monoclonal antibodies administered via infusion, clinic infrastructure will need to quickly adapt to select patients most appropriate for newly available therapy, demonstrate patient eligibility, provide on-site resources and equipment for patients and clinicians, and work with managed care to ensure coverage for these therapies.2-4 Changes on this scale will be challenging for everyone, ranging from small, private practices to large clinics at academic centers, and it is in clinicians’ and patients’ best interest to begin preparation for the coming changes now. Dr. Sabbagh provides his expert insight into how clinicians can prepare for significant changes in clinic infrastructure, the types of protocols that will be necessary, and strategies to work with managed care to facilitate patient access to newly approved therapies.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1)1:1-4.
  3. Fleming WK, et al. JAMA Health Forum. 2020;1(9):e201148-e201148.
  4. Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Free CME/AANP
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Detail clinical infrastructure changes that may be needed to address the growing population of patients with AD and new treatment options

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Though there are currently only symptomatic therapies available, amyloid- and tau-targeted therapies are on the horizon. With the approval of new therapies for AD, particularly monoclonal antibodies administered via infusion, clinic infrastructure will need to quickly adapt to select patients most appropriate for newly available therapy, demonstrate patient eligibility, provide on-site resources and equipment for patients and clinicians, and work with managed care to ensure coverage for these therapies.2-4 Changes on this scale will be challenging for everyone, ranging from small, private practices to large clinics at academic centers, and it is in clinicians’ and patients’ best interest to begin preparation for the coming changes now. Dr. Sabbagh provides his expert insight into how clinicians can prepare for significant changes in clinic infrastructure, the types of protocols that will be necessary, and strategies to work with managed care to facilitate patient access to newly approved therapies.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1)1:1-4.
  3. Fleming WK, et al. JAMA Health Forum. 2020;1(9):e201148-e201148.
  4. Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

0.50 AANP / CME
Global Education Group
Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 2: The Evolving Management Landscape in Alzheimer’s Disease: From Pathophysiology to Emerging Therapies

Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 2: The Evolving Management Landscape in Alzheimer’s Disease: From Pathophysiology to Emerging Therapies

Start

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss clinically relevant aspects of AD pathophysiology, including amyloid β and tau
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Barring significant clinical efforts and medical breakthroughs that prevent or slow disease development, current estimates suggest that by 2050, AD will afflict 14 million patients in the United States.1 Clearly, the development of AD is complex, presenting a target-rich clinical environment for both diagnostic approaches and therapeutic interventions. Amyloid plaques and neurofibrillary tangles are the primary pathophysiologic characteristics of AD.2 Among other approaches, amyloid-targeted therapies have been directed toward protofibrils, monomers, oligomers, and existing plaques.3 Neurofibrillary tangles have emerged as another therapeutic target over the last several years, including agents targeting tau expression, stabilizing tau conformations, or clearing tau aggregates.4 Thus far, amyloid-targeted therapies are further advanced in clinical development, and as the potential for approval grows, clinicians must be aware of mechanism of action, clinical trial data, and patient selection. In this activity, Dr. Cohen reviews the pathophysiology of AD, individual therapeutic targets, and amyloid- and tau-directed therapies as well as other therapeutic approaches.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Jeong S. Mol Cells. 2017;40(9):613-620.
  3. Panza F, et al. Nat Rev Neurol. 2019;15(2):73-88.
  4. Graham WV, et al. Annu Rev Med. 2017;68:413-430.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Free CME/AANP
0.50 AMA PRA Category 1 Credit(s)
0.50 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss clinically relevant aspects of AD pathophysiology, including amyloid β and tau
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Barring significant clinical efforts and medical breakthroughs that prevent or slow disease development, current estimates suggest that by 2050, AD will afflict 14 million patients in the United States.1 Clearly, the development of AD is complex, presenting a target-rich clinical environment for both diagnostic approaches and therapeutic interventions. Amyloid plaques and neurofibrillary tangles are the primary pathophysiologic characteristics of AD.2 Among other approaches, amyloid-targeted therapies have been directed toward protofibrils, monomers, oligomers, and existing plaques.3 Neurofibrillary tangles have emerged as another therapeutic target over the last several years, including agents targeting tau expression, stabilizing tau conformations, or clearing tau aggregates.4 Thus far, amyloid-targeted therapies are further advanced in clinical development, and as the potential for approval grows, clinicians must be aware of mechanism of action, clinical trial data, and patient selection. In this activity, Dr. Cohen reviews the pathophysiology of AD, individual therapeutic targets, and amyloid- and tau-directed therapies as well as other therapeutic approaches.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Jeong S. Mol Cells. 2017;40(9):613-620.
  3. Panza F, et al. Nat Rev Neurol. 2019;15(2):73-88.
  4. Graham WV, et al. Annu Rev Med. 2017;68:413-430.

Faculty

Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour (which includes 0.2 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 70% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

0.25 AANP / CME
Global Education Group
Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 3: Managing Alzheimer’s Disease: Where Are We Now and Where Are We Going?

Evolving Approaches to Alzheimer’s Disease: Finding the Way Forward—Activity 3: Managing Alzheimer’s Disease: Where Are We Now and Where Are We Going?

Start

Activity Details

Free CME/AANP
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Assess patients with mild cognitive impairment and AD using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Early diagnosis of AD is shaped by patient and caregiver interviews, cognitive testing, and standard imaging. Once diagnosed, patients and their caregivers face numerous challenges, all of which require longitudinal treatment, ongoing monitoring, and an intensive commitment to patient/caregiver education and engagement. Symptomatic therapies are available for patients with AD. The range of neurotransmitter-focused medications, however, is limited.1 There is a plethora of evidence suggesting active management can improve quality of life if performed correctly. This requires collaborative care, which should include patients and caregivers, education, comorbidity management, social interaction, and appropriate use of available treatments.1 Amyloid- and tau-targeted therapies are in clinical trials, and, if approved, these therapies would change the landscape of AD management.2,3 It is critical for clinicians to be well educated about current management strategies, collaborative care, patient education, and emerging therapies and patient selection. This self-assessment activity presents real-life case scenarios for clinicians to gauge and learn about optimal practice strategies for diagnosis and management of AD, as well as how emerging therapies may eventually be employed.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Budd Haeberlein S, et al. Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
  3. Congdon EE, Sigurdsson EM. Nat Rev Neurol. 2018;14(7):399-415.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Free CME/AANP
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: May 11, 2021
Expires: May 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Assess patients with mild cognitive impairment and AD using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Early diagnosis of AD is shaped by patient and caregiver interviews, cognitive testing, and standard imaging. Once diagnosed, patients and their caregivers face numerous challenges, all of which require longitudinal treatment, ongoing monitoring, and an intensive commitment to patient/caregiver education and engagement. Symptomatic therapies are available for patients with AD. The range of neurotransmitter-focused medications, however, is limited.1 There is a plethora of evidence suggesting active management can improve quality of life if performed correctly. This requires collaborative care, which should include patients and caregivers, education, comorbidity management, social interaction, and appropriate use of available treatments.1 Amyloid- and tau-targeted therapies are in clinical trials, and, if approved, these therapies would change the landscape of AD management.2,3 It is critical for clinicians to be well educated about current management strategies, collaborative care, patient education, and emerging therapies and patient selection. This self-assessment activity presents real-life case scenarios for clinicians to gauge and learn about optimal practice strategies for diagnosis and management of AD, as well as how emerging therapies may eventually be employed.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Budd Haeberlein S, et al. Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
  3. Congdon EE, Sigurdsson EM. Nat Rev Neurol. 2018;14(7):399-415.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

0.75 CME / MOC
Vindico
Seeking a Cure for Alzheimer’s Disease: A Virtual Poster Hall Activity

Seeking a Cure for Alzheimer’s Disease: A Virtual Poster Hall Activity

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: April 15, 2021
Expires: April 14, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. This digital poster hall activity will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. It will also review the current understanding of the pathophysiology of AD and the latest evidence-based strategies for an early and accurate diagnosis.

Faculty

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: April 15, 2021
Expires: April 14, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. This digital poster hall activity will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. It will also review the current understanding of the pathophysiology of AD and the latest evidence-based strategies for an early and accurate diagnosis.

Faculty

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 AAPA / CME / CNE / CPE
Vindico
Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Start

Activity Details

Free CME, CNE, CPE, AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1.0 AAPA Category 1 CME credit(s)
Released: March 12, 2021
Expires: March 11, 2022
60 minutes to complete

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
  • Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
  • Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva


Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME, CNE, CPE, AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1.0 AAPA Category 1 CME credit(s)
Released: March 12, 2021
Expires: March 11, 2022
60 minutes to complete

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
  • Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
  • Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva


Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

1.00 CME / MOC
Vindico
Seeking a Cure for Alzheimer’s Disease: Is There Hope?

Seeking a Cure for Alzheimer’s Disease: Is There Hope?

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: February 28, 2021
Expires: February 27, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
  • Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon


Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: February 28, 2021
Expires: February 27, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, psychiatrists, primary care physicians, geriatric physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the current understanding of the pathophysiology of Alzheimer’s disease (AD) and the latest evidence-based strategies and modalities for the early and accurate diagnosis of patients with AD.
  • Review the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD.
  • Assess the role of multidisciplinary collaborative care models for the management of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. Current therapies delay cognitive decline in some patients, but they do not treat the underlying causes of the disease nor do they halt the progression of the disease. Despite the significant burden on patients, there remains no approved disease-modifying therapy to treat patients with AD. In this program, expert faculty will provide guidance on the mechanisms of action, clinical endpoints, and latest clinical evidence regarding new and emerging agents for the treatment of patients with AD. They will also discuss the current understanding of the pathophysiology of AD; the latest evidence-based strategies for an early and accurate diagnosis; as well as the role of multidisciplinary, collaborative-care models for the management of patients with AD.

Agenda

Introduction
Marwan Noel Sabbagh, MD, FAAN, CCRI

Critical Importance of Early Diagnosis
Sharon Cohen, MD, FRCPC

Panel Discussion

Current and Emerging Therapies for Alzheimer’s Disease
Anton P. Porsteinsson, MD

Panel Discussion

Collaborative Care Models for Alzheimer’s Disease
Marwan Noel Sabbagh, MD, FAAN, CCRI

Panel Discussion and Conclusion

Activity Chair

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute on Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMETHOD Health, Versanum

Faculty

Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
Rochester, NY

Disclosure:
Consulting Fee: Acadia, Avanir, Biogen, Cadent Therapeutics, Functional Neuromodulation, MapLight Therapeutics, Premier Healthcare Solutions, Sunovion, Syneos
Contracted Research: Alector, Athira, Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Vaccinex
Scientific Advisory Board: Alzheon


Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator
Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CNE
Vindico
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 28, 2021
Expires: February 27, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
  • Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA

Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Pages